Colorado’s HB26-1325 became law after Gov. signed it on June 4, 2026, according to the Colorado General Assembly. The measure establishes an ibogaine research pilot program within the Behavioral Health Administration to examine safety and effectiveness for treating mental health conditions and substance use disorders. The administration may select up to five pilot sites, but the program depends on receiving enough gifts, grants and donations to operate and help finance those sites. The law directs the administration to create a committee to review site applications and recommend which applicants to accept. It also calls on the agency to seek federal research and development funding, including through the Advanced Research Projects Agency for Health. The General Assembly’s page lists Aug. 12, 2026, as the effective date for the session law, Chapter 372, titled “Natural Medicine.” Beyond the research program, HB26-1325 revises rules for Colorado’s natural medicine system. It allows licensing authorities to adopt rules on ibogaine’s administration, manufacture and use, and sets out new licensing provisions for sales and temporary premises. The law also provides that facilitators are not liable for certain participant injuries unless intentional misconduct, gross negligence or a departure from the recognized standard of care caused them. Licensees seeking to cultivate, manufacture, dispense or administer ibogaine must establish a benefit-sharing plan in consultation with Indigenous communities. For mushroom readers, the legislation is notable as a state-level expansion and adjustment of natural medicine regulation, though its pilot focuses on ibogaine, not mushrooms. The source describes it as a research program, not a recommendation to use the substance.